title: Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS.
abstract: OBJECTIVE
  Alemtuzumab exerts its clinical efficacy by its specific pattern of depletion and repopulation of different immune cells. Beyond long-term immunologic and clinical data, little is known about acute changes in immunologic and routine laboratory parameters and their clinical relevance during the initial alemtuzumab infusion.
  
  
  METHODS
  Fifteen patients with highly active MS were recruited. In addition to parameters including heart rate, blood pressure, body temperature, and monitoring of adverse events, complete blood cell count, liver enzymes, kidney function, acute-phase proteins, serum cytokine profile, complement activation, peripheral immune cell distribution, and their potential of cytokine release were investigated prior to and after methylprednisolone and after alemtuzumab on each day of alemtuzumab infusion.
  
  
  RESULTS
  After the first alemtuzumab infusion, both the total leukocyte and granulocyte counts markedly increased, whereas lymphocyte counts dramatically decreased. In addition to lymphocyte depletion, cell subtypes important for innate immunity also decreased within the first week after alemtuzumab infusion. Although patients reported feeling well, C-reactive protein and procalcitonin peaked at serum levels consistent with septic conditions. Increases in liver enzymes were detected, although kidney function remained stable. Proinflammatory serum cytokine levels clearly rose after the first alemtuzumab infusion. Alemtuzumab led to impaired cytokine release ex vivo in nondepleted cells. Normal clinical parameters and mild adverse events were presented.
  
  
  CONCLUSIONS
  Dramatic immunologic effects were observed. Standardized infusion procedure and pretreatment management attenuated infusion-related reactions. Alemtuzumab-mediated effects led to artificially altered parameters in standard blood testing. We recommend clinical decision-making based on primarily clinical symptoms within the first alemtuzumab treatment week.
authors.affiliation: Center of Clinical Neuroscience, University Hospital, Dresden, Germany.
authors.forename: Katja
authors.initials: K
authors.lastname: Thomas
authors.affiliation: Center of Clinical Neuroscience, University Hospital, Dresden, Germany.
authors.forename: Judith
authors.initials: J
authors.lastname: Eisele
authors.affiliation: Center of Clinical Neuroscience, University Hospital, Dresden, Germany.
authors.forename: Francisco Alejandro
authors.initials: FA
authors.lastname: Rodriguez-Leal
authors.affiliation: Center of Clinical Neuroscience, University Hospital, Dresden, Germany.
authors.forename: Undine
authors.initials: U
authors.lastname: Hainke
authors.affiliation: Center of Clinical Neuroscience, University Hospital, Dresden, Germany.
authors.forename: Tjalf
authors.initials: T
authors.lastname: Ziemssen